Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review

Daptomycin Dosing Based on Ideal Body Weight versus Actual Body Weight: Comparison of Clinical Outcomes

(2013) Jennifer K. Ng et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of Intravenous Voriconazole in Obese Patients: Implications ofCYP2C19Homozygous Poor Metabolizer Genotype

(2013) Brad Moriyama et al.   PHARMACOTHERAPY

Voriconazole Serum Concentrations in Obese and Overweight Immunocompromised Patients: A Retrospective Review

(2013) Samantha Davies-Vorbrodt et al.   PHARMACOTHERAPY

Safety and Effectiveness of Daptomycin Across a Hospitalized Obese Population: Results of a Multicenter Investigation in the Southeastern United States

(2013) P. Brandon Bookstaver et al.   PHARMACOTHERAPY

Vancomycin Trough Concentrations in Overweight or Obese Pediatric Patients

(2013) Daniel E. Heble et al.   PHARMACOTHERAPY

Performance of a vancomycin dosage regimen developed for obese patients

(2012) D. C. Reynolds et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Case-Control Study of Drug Monitoring of  -Lactams in Obese Critically Ill Patients

(2012) M. Hites et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Incidence and Predictors of Nephrotoxicity Associated with Intravenous Colistin in Overweight and Obese Patients

(2012) Timothy P. Gauthier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of Obesity on Drug Metabolism and Elimination in Adults and Children

(2012) Margreke J.E. Brill et al.   CLINICAL PHARMACOKINETICS

Evaluation of the effect of obesity on voriconazole serum concentrations

(2012) E. Koselke et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Obesity and respiratory infections: Does excess adiposity weigh down host defense?

(2012) Peter Mancuso   PULMONARY PHARMACOLOGY & THERAPEUTICS

Determining vancomycin clearance in an overweight and obese population

(2011) J. V. B. Leong et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

TDM-Guided Therapy with Daptomycin and Meropenem in a Morbidly Obese, Critically Ill Patient

(2011) Federico Pea et al.   ANNALS OF PHARMACOTHERAPY

Steady-State Plasma Pharmacokinetics of Oral Voriconazole in Obese Adults

(2011) Manjunath P. Pai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Simplified Estimation of Aminoglycoside Pharmacokinetics in Underweight and Obese Adult Patients

(2011) Manjunath P. Pai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients

(2011) S. M. Garonzik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dosing Voriconazole in an Obese Patient

(2011) N. J. Dickmeyer et al.   CLINICAL INFECTIOUS DISEASES

Incidence of and Risk Factors for Colistin-Associated Nephrotoxicity in a Large Academic Health System

(2011) J. M. Pogue et al.   CLINICAL INFECTIOUS DISEASES

Implications of Obesity for Drug Therapy: Limitations and Challenges

(2011) R Jain et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction

(2011) Brad Moriyama et al.   MYCOSES

Colistin Dosing and Nephrotoxicity in a Large Community Teaching Hospital

(2010) C. A. DeRyke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and Endocarditis

(2010) Sujata M. Bhavnani et al.   CLINICAL INFECTIOUS DISEASES

Effect of Obesity on the Pharmacokinetics of Drugs in Humans

(2010) Michael J. Hanley et al.   CLINICAL PHARMACOKINETICS

Acyclovir-induced renal failure in an obese patient

(2009) J. O. Hernandez et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever

(2008) J. S. Bubalo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY